Viking Therapeutics Inc (NASDAQ:VKTX) Posts Wider Q2 2025 Loss, Shares Drop in After-Hours Trading

Viking Therapeutics Inc (NASDAQ:VKTX) Reports Q2 2025 Earnings: Wider Loss Than Expected, Shares Dip in After-Hours Trading

Viking Therapeutics Inc, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its second-quarter 2025 financial results after market close on July 23, 2025. The company posted a wider-than-expected loss, leading to a negative reaction in after-hours trading.

Key Financial Highlights

• Revenue: Reported revenue for Q2 2025 was $0.0, in line with analyst estimates.
• Earnings Per Share (EPS): The company reported a loss of $0.58 per share, missing the consensus estimate of -$0.4553 by a significant margin.
• Market Reaction: Following the earnings release, shares fell ~5.7% in after-hours trading, reflecting investor disappointment over the larger-than-anticipated loss.

Performance Context

Despite the post-earnings dip, Viking Therapeutics' stock has shown resilience over the past month, gaining 29.1%. However, short-term performance remains muted, with a 0.06% increase over the last two weeks and a 0.05% uptick in the past week.

Analyst Estimates for Future Quarters

Looking ahead, analysts expect continued challenges in profitability:

• Q3 2025 Revenue Estimate: $0.0
• Q3 2025 EPS Estimate: -$0.5057
• Full-Year 2025 Revenue Estimate: $1.5 million (primarily from potential milestone payments or collaborations)
• Full-Year 2025 EPS Estimate: -$1.93

Given the lack of revenue generation, investor focus remains on the company’s clinical pipeline progress rather than near-term financial performance.

Corporate and Clinical Updates

While the press release did not provide explicit forward guidance, Viking Therapeutics highlighted ongoing developments in its clinical programs:

• VK2809: A Phase IIb study for non-alcoholic steatohepatitis (NASH) and fibrosis remains a key focus.
• VK0214: Development continues for X-linked adrenoleukodystrophy (X-ALD), a rare neurological disorder.
• VK2735: The dual GLP-1/GIP receptor agonist for metabolic disorders is another promising candidate in the pipeline.

The absence of revenue-generating products means the company’s valuation hinges heavily on clinical trial outcomes and potential partnerships.

Conclusion

Viking Therapeutics’ Q2 earnings miss underscores the inherent risks of investing in clinical-stage biotech firms, where financial performance is secondary to pipeline progress. The after-hours sell-off suggests investor caution, but the stock’s recent monthly gains indicate optimism around its long-term prospects.

For a deeper dive into Viking Therapeutics’ earnings history and future estimates, visit the earnings and estimates page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.